Ramucirumab, an anti-VEGFR2 monoclonal antibody which blocks the binding of VEGF-A, -C and -D) is approved in combination with paclitaxel based on findings from the phase 3 RAINBOW trial which demonstrated that combining ramucirumab with paclitaxel significantly prolonged survival compared with paclitaxel alone in previously treated or advanced OGJ and GC tumours (9.63 versus 7.26 months, respectively) (Vita et al. 2019). Here, KDR is linked to neoplasm.